Implementing artificial intelligence (AI) to facilitate health outcomes in mood disorders: Application versus aspiration.

Roger S McIntyre¹, Charles B Nemeroff², Natalie Rasgon³

¹Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Department of Pharmacology & Toxicology, University of Toronto, ON, Canada. Electronic address: roger.mcintyre@bcdf.org.

²Department of Psychiatry and Behavioral Sciences, University of Texas at Austin, Dell Medical School, Austin, TX, United States of America. Electronic address: cnemeroff@austin.utexas.edu.

³Department of Psychiatry, Icahn School of Medicine at Mount Sinai, United States of America; Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine, United States of America. Electronic address: nrasgon@stanford.edu.

PubMed DOI

Abstract

The burden of depressive and bipolar disorders at the individual and societal level are extraordinary and increasing. For decades, evidence-based treatments for these conditions have been established but outcomes amongst individuals with lived experience remains suboptimal. Notwithstanding calls to close gaps between current practice and best practice, there is an absence of evidence that overall…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.